Denmark invests in mucosal vaccines

Denmark invests in mucosal vaccines

The Novo Nordisk Foundation in December committed $260 million to create new vaccines for deadly respiratory diseases in partnership with the University of Copenhagen. The new Novo Nordisk Foundation Initiative for Vaccines and Immunity will focus on mucosal vaccines that generate an immune response in the airways themselves, at the site of infection. “[This strategy] is a relatively unexplored area of research with astounding potential,” noted vaccine specialist Peter Lawætz Andersen of the Novo Nordisk Foundation in a press release. Unlike systemic vaccines, after which recipients can still become infected and pass the infection to others, mucosal vaccines have the potential to block infection and prevent airborne transmission.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

209,00 € per year

only 17,42 € per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

About this article

Cite this article

Denmark invests in mucosal vaccines.
Nat Biotechnol42, 5 (2024). https://doi.org/10.1038/s41587-023-02104-z

Download citation

Published: 17 January 2024

Issue Date: January 2024

DOI: https://doi.org/10.1038/s41587-023-02104-z

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-02104-z

Exit mobile version